Abstract:Background: All patients with EGFR mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI). In up to 30% of patients, the mechanism of acquired resistance remains unknown. MicroRNAs (miRNAs) represent a category of small non-coding RNAs commonly dysregulated in human malignancies and have been implicated in therapy resistance. The aim of this study was to understand the role of novel miRNAs in acquired EGFR TKI resistance in EGFR-mutant NSCLC. Method: The miR-483-3p expression in in vitro and in vivo models of acquired gefitinib resistance was examined by miRNA microarray and real-time RT-PCR. Transient or stable gain- and loss-of-function experiments were conducted in cell lines and nude mice, to evaluate the effects of miR-483-3p on sensitivity to gefitinib, proliferation, apoptosis, EMT and migration/invasion in vitro and in vivo. The molecular pathways affected by miR-483-3p were characterized using in silico target prediction, dual luciferase reporter assays and overexpression rescue experiments. The role of promoter methylation in miR-483-3p silencing was examined by real-time RT-PCR after demethylating agents treatment. Result: In this study, we reported the silencing of miR-483-3p and evidence for epithelial-to-mesenchymal transition (EMT) in both in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to gefitinib. In those tumor models, forced expression of miR-483-3p effectively increased sensitivity of gefitinib-resistant lung cancer cells to gefitinib by inhibiting proliferation, promoting apoptosis and reversing EMT phenotype. Mechanistically, miR-483-3p directly targeted integrin beta3, and thus repressed downstream FAK/Erk signaling pathway. In addition, miR-483-3p silencing in gefitinib-resistant NSCLC was due to hypermethylation of its own promoter. Conclusion: Our study provides a novel mechanism that epigenetic silencing of miR-483-3p promotes acquired EGFR TKI resistance in EGFR-mutant NSCLC by targeting integrin beta3. miR-483-3p may present a promising therapeutic target to overcome acquired resistance.The work was supported by National Natural Science Foundation of China (81372522 and 81773747), Science and Technology Commission of Shanghai Municipality (12ZR1416000 and 12140901400).

Reciprocal regulation of miR-206 and IL-6/STAT3 pathway mediates IL6-induced gefitinib resistance in EGFR-mutant lung cancer cells

Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

MiR-128 Reverses the Gefitinib Resistance of the Lung Cancer Stem Cells by Inhibiting the C-Met/pi3k/akt Pathway.

MiR-142-5p Reverses the Resistance to Gefitinib Through Targeting HOXD8 in Lung Cancer Cells.

Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance in EGFR-mutant NSCLC by targeting integrin beta3

MicroRNA-34a Overcomes HGF-mediated Gefitinib Resistance in EGFR Mutant Lung Cancer Cells Partly by Targeting MET.

MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines

Epigenetic Silencing of Mir-483-3p Promotes Acquired Gefitinib Resistance and EMT in EGFR-mutant NSCLC by Targeting Integrin Β3

Gefitinib-Resistance is Related to Bim Expression in Non-Small Cell Lung Cancer Cell Lines

Downregulation of HOXC6 by Mir-27A Ameliorates Gefitinib Resistance in Non-Small Cell Lung Cancer

MEF2C promotes gefitinib resistance in hepatic cancer cells through regulating MIG6 transcription.

Microrna Expression Profiles Associated with Acquired Gefitinib-Resistance in Human Lung Adenocarcinoma Cells

IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer

Microrna Expression Prohles in Acquired Gehtinib-Resistant Human Lung Adenocarcinoma Cell Line PC9/AB2 Vs Its Parental Cell Line PC9

Selumetinib overcomes gefitinib primary and acquired resistance by regulating MIG6/STAT3 in NSCLC

Study on effect and mechanisms of IL-6 induced Gefitinib resistance in non-small cell lung cancer

An Autocrine IL-6/IGF-1R Loop Mediates EMT and Promotes Tumor Growth in Non-small Cell Lung Cancer

Interleukin-6 Identified As an Important Factor in Hypoxia- and Aldehyde Dehydrogenase-Based Gefitinib Adaptive Resistance in Non-Small Cell Lung Cancer Cells.

MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines

MicroRNA‑506‑3p Reverses Gefitinib Resistance in Non‑small Cell Lung Cancer by Targeting Yes‑associated Protein 1.

Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer